Andy Osborne

Vice President of Pre-Clinical Research at Ikarovec

Speaker

Andy Osborne has over a decade of experience developing innovative therapies for retinal and back-of-the-eye diseases. At the University of Cambridge and Quethera, he led the development of the first bicistronic gene therapy for glaucoma, which was acquired by Astellas. He subsequently helped establish Ikarovec, where he leads preclinical research developing multi-target gene therapies for complex retinal disorders.